These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 1829915)

  • 1. Bepridil in combination with anthracyclines to reverse anthracycline resistance in cancer patients.
    van Kalken CK; van der Hoeven JJ; de Jong J; Giaccone G; Schuurhuis GJ; Maessen PA; Blokhuis WM; van der Vijgh WJ; Pinedo HM
    Eur J Cancer; 1991; 27(6):739-44. PubMed ID: 1829915
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical and pharmacologic study of multidrug resistance reversal with vinblastine and bepridil.
    Linn SC; van Kalken CK; van Tellingen O; van der Valk P; van Groeningen CJ; Kuiper CM; Pinedo HM; Giaccone G
    J Clin Oncol; 1994 Apr; 12(4):812-9. PubMed ID: 7908691
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Anthracycline antibiotics in cancer therapy. Focus on drug resistance.
    Booser DJ; Hortobagyi GN
    Drugs; 1994 Feb; 47(2):223-58. PubMed ID: 7512899
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase II study of dexverapamil plus anthracycline in patients with metastatic breast cancer who have progressed on the same anthracycline regimen.
    Warner E; Hedley D; Andrulis I; Myers R; Trudeau M; Warr D; Pritchard KI; Blackstein M; Goss PE; Franssen E; Roche K; Knight S; Webster S; Fraser RA; Oldfield S; Hill W; Kates R
    Clin Cancer Res; 1998 Jun; 4(6):1451-7. PubMed ID: 9626462
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Potentiation of doxorubicin cytotoxicity by the calcium antagonist bepridil in anthracycline-resistant and -sensitive cell lines. A comparison with verapamil.
    Schuurhuis GJ; Broxterman HJ; van der Hoeven JJ; Pinedo HM; Lankelma J
    Cancer Chemother Pharmacol; 1987; 20(4):285-90. PubMed ID: 3500807
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dexrazoxane. A review of its use as a cardioprotective agent in patients receiving anthracycline-based chemotherapy.
    Wiseman LR; Spencer CM
    Drugs; 1998 Sep; 56(3):385-403. PubMed ID: 9777314
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety and efficacy of the multidrug-resistance inhibitor biricodar (VX-710) with concurrent doxorubicin in patients with anthracycline-resistant advanced soft tissue sarcoma.
    Bramwell VH; Morris D; Ernst DS; Hings I; Blackstein M; Venner PM; Ette EI; Harding MW; Waxman A; Demetri GD
    Clin Cancer Res; 2002 Feb; 8(2):383-93. PubMed ID: 11839653
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combining platinum, paclitaxel and anthracycline in patients with advanced gynaecological malignancy.
    Gregory RK; Hill ME; Moore J; A'Hern RP; Johnston SR; Blake P; Shephard J; Barton D; Gore ME
    Eur J Cancer; 2000 Mar; 36(4):503-7. PubMed ID: 10717527
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Current options in treatment of anthracycline-resistant breast cancer.
    Kröger N; Achterrath W; Hegewisch-Becker S; Mross K; Zander AR
    Cancer Treat Rev; 1999 Oct; 25(5):279-91. PubMed ID: 10544072
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Reflections on the development of resistance during therapy for advanced breast cancer. Implications of high levels of activity of docetaxel in anthracycline-resistant breast cancer patients.
    Ravdin PM
    Eur J Cancer; 1997 Aug; 33 Suppl 7():S7-10. PubMed ID: 9486096
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prospective evaluation of cardiotoxicity during a six-hour doxorubicin infusion regimen in women with adenocarcinoma of the breast.
    Speyer JL; Green MD; Dubin N; Blum RH; Wernz JC; Roses D; Sanger J; Muggia FM
    Am J Med; 1985 Apr; 78(4):555-63. PubMed ID: 3838618
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A phase II trial of mitomycin C, 5'-deoxy-5-fluorouridine, etoposide and medroxyprogesterone acetate (McVD-MPA) as a salvage chemotherapy to anthracycline-resistant tumor in relapsed breast cancer and its mechanism(s) of antitumor action.
    Kim R; Osaki A; Tanabe K; Kojima J; Toge T
    Oncol Rep; 2001; 8(3):597-603. PubMed ID: 11295087
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A phase I clinical and pharmacokinetic study of the multi-drug resistance protein-1 (MRP-1) inhibitor sulindac, in combination with epirubicin in patients with advanced cancer.
    O'Connor R; O'Leary M; Ballot J; Collins CD; Kinsella P; Mager DE; Arnold RD; O'Driscoll L; Larkin A; Kennedy S; Fennelly D; Clynes M; Crown J
    Cancer Chemother Pharmacol; 2007 Jan; 59(1):79-87. PubMed ID: 16642371
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Use of dexrazoxane as a cardioprotectant in patients receiving doxorubicin or epirubicin chemotherapy for the treatment of cancer. The Provincial Systemic Treatment Disease Site Group.
    Seymour L; Bramwell V; Moran LA
    Cancer Prev Control; 1999 Apr; 3(2):145-59. PubMed ID: 10474762
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A dose-finding study of epirubicin in combination with paclitaxel in the treatment of advanced breast cancer.
    Conte PF; Michelotti A; Baldini E; Salvadori B; Gennari A; Da Prato M; Tibaldi C; Salzano E; Gentile A
    Semin Oncol; 1996 Oct; 23(5 Suppl 11):28-31. PubMed ID: 8893896
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase I/II trial of the multidrug-resistance modulator valspodar combined with cisplatin and doxorubicin in refractory ovarian cancer.
    Baekelandt M; Lehne G; Tropé CG; Szántó I; Pfeiffer P; Gustavssson B; Kristensen GB
    J Clin Oncol; 2001 Jun; 19(12):2983-93. PubMed ID: 11408493
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Five-day infusion of fluorouracil and vinorelbine for advanced breast cancer patients treated previously with anthracyclines.
    Pieńkowski T; Jagiello-Gruszfeld A
    Int J Clin Pharmacol Res; 2001; 21(3-4):111-7. PubMed ID: 12067140
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase IB study of doxorubicin in combination with the multidrug resistance reversing agent S9788 in advanced colorectal and renal cell cancer.
    Punt CJ; Voest EE; Tueni E; Van Oosterom AT; Backx A; De Mulder PH; Hecquet B; Lucas C; Gerard B; Bleiberg H
    Br J Cancer; 1997; 76(10):1376-81. PubMed ID: 9374386
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacokinetic optimisation of treatment schedules for anthracyclines and paclitaxel in patients with cancer.
    Danesi R; Conte PF; Del Tacca M
    Clin Pharmacokinet; 1999 Sep; 37(3):195-211. PubMed ID: 10511918
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Paclitaxel combined with weekly high-dose 5-fluorouracil/folinic acid and cisplatin in the treatment of advanced breast cancer.
    Klaassen U; Wilke H; Seeber S
    Semin Oncol; 1996 Oct; 23(5 Suppl 11):32-7. PubMed ID: 8893897
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.